<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="ctdna-mrd-phasedseq-dlbcl-chamuleau">
    <meta name="study:title" content="S240 - ctDNA-MRD by PhasED-Seq in 1L DLBCL (HOVON-902)">
    <meta name="study:fileName" content="Abstracts/CTDNA-MRD-PHASEDSEQ-DLBCL-CHAMULEAU-S240.html">
    <meta name="study:cancerTypes" content="DLBCL,HGBL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Rituximab,Monoclonal Antibody,Chemotherapy,CIT">

    <title>S240: ctDNA-MRD by PhasED-Seq in 1L DLBCL (HOVON-902) (Chamuleau) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="embargo-notice">
            <p><strong>EMBARGOED:</strong> This abstract is embargoed until Thursday, June 12, 2025, 08:00 CEST.</p>
        </div>

        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: S240 - EOT ctDNA-MRD Prognosis in 1L DLBCL (PhasED-Seq)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim</h4>
                    <p>Population: N=150 1L DLBCL/HGBL/PBMCL (HOVON-902). Aim: Validate prognostic value of EOT ctDNA-MRD (PhasED-Seq).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M2.25 2.25a.75.75 0 000 1.5H3v10.5a3 3 0 003 3h1.21l-2.12 2.121a.75.75 0 001.06 1.061l2.38-2.381a3.75 3.75 0 005.021 0l2.38 2.38a.75.75 0 101.06-1.06L14.79 18H16a3 3 0 003-3V3.75h.75a.75.75 0 000-1.5H2.25zm6.54 3.75a.75.75 0 01.04-.325l2.5-6.5a.75.75 0 011.42.55l-2.5 6.5a.75.75 0 01-1.46-.225z" clip-rule="evenodd" />
                    </svg>
                    <h4>Method & Therapy</h4>
                    <p>Method: PhasED-Seq for MRD (EOT plasma). Therapy: 1L R-CHOP or DA-EPOCH-R.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M4.5 19.5a3 3 0 003 3h9a3 3 0 003-3v-1.5a.75.75 0 00-1.5 0V18a1.5 1.5 0 01-1.5 1.5h-9A1.5 1.5 0 016 18v-1.5a.75.75 0 00-1.5 0V19.5zM4.5 8.25A.75.75 0 015.25 9v3.75a.75.75 0 01-1.5 0V9a.75.75 0 01-.75-.75zM19.5 8.25a.75.75 0 00-.75.75v3.75a.75.75 0 001.5 0V9a.75.75 0 00-.75-.75z" /><path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zM8.31 8.47a.75.75 0 00-1.06 1.06L10.94 12l-3.69 3.69a.75.75 0 101.06 1.06L12 13.06l3.69 3.69a.75.75 0 101.06-1.06L13.06 12l3.69-3.69a.75.75 0 10-1.06-1.06L12 10.94 8.31 8.47z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Prognostic Finding (PFS)</h4>
                    <p>EOT MRD+ vs MRD-: 2-year PFS: <span class="highlight-value">28% vs 88%</span> (HR 9.7, p&lt;0.0001).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Finding (OS) & Conclusion</h4>
                    <p>EOT MRD+ vs MRD-: 2-year OS: <span class="highlight-value">50% vs 97%</span> (HR 10.6, p&lt;0.0001). Conclusion: ctDNA-MRD robustly predicts outcome.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">S240 - Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national HOVON trial</h1>
            <p class="abstract-sub-header">Martine Chamuleau, Steven Wang, Marcel Nijland, Leonie Strobbe, Margriet Oosterveld, Rinske Boersma, Harry Koene, Clara P.W. Klerk, Eva de Jongh, Ad Koster, Hans Pruijt, Marjolein Van der Poel, Erik van Werkhoven, Avinash Dinmohamed, Sandra Close, Krystal Brown, Stephanie Meek, Ash Alizadeh, David Kurtz</p>
            <p class="abstract-meta-info mt-2">EHA2025 Congress | Abstract #S240 | Oral Presentation | Session: Aggressive Non-Hodgkin lymphoma - Clinical (Observational)</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>The prognostic utility of circulating tumor DNA measurable residual disease (ctDNA-MRD) detection at end of treatment (EOT) using phased variant (PV) enrichment and detection sequencing (PhasED-Seq) has been demonstrated in patients with diffuse large B-cell lymphoma (DLBCL) receiving first-line (1L) therapy.</li>
                        <li>Prior studies are limited by treatment, patient, and sample heterogeneity.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To independently validate the prognostic value of PhasED-Seq in a national, multi-center study of uniformly treated 1L DLBCL patients.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Study Population: LBCL patients enrolled on HOVON-902 trial, a real-world observational cohort from >50 centers in the Netherlands and Belgium.</li>
                        <li>Treatment: Patients received curative-intent 1L therapy (R-CHOP or DA-EPOCH-R).</li>
                        <li>ctDNA-MRD Assessment: Assessed using Foresight CLARITY. Phased variants (PVs) identified from pretreatment biopsies or plasma with matched normal DNA. EOT plasma samples used for ctDNA-MRD detection.</li>
                        <li>Endpoints: Prognostic significance of MRD status (positive [+], negative [-]) on progression-free survival (PFS) and overall survival (OS).</li>
                    </ul>
                    <div class="study-design-schema">
                        <h3 class="schema-title">HOVON-902 Sub-Study: ctDNA-MRD Prognostic Validation</h3>
                        <div class="schema-enrollment">
                            <strong>LBCL Pts on HOVON-902 (N=150 analyzed)</strong>
                            <span>1L R-CHOP or DA-EPOCH-R</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                             <div class="schema-phase" style="flex-basis: 48%;">
                                <strong>Pre-treatment</strong>
                                <span>Biopsy/Plasma for PV ID</span>
                            </div>
                            <div class="schema-arrow schema-arrow-horizontal" style="writing-mode: horizontal-tb; align-self: center;">➔</div>
                             <div class="schema-phase" style="flex-basis: 48%;">
                                <strong>End of Treatment (EOT)</strong>
                                <span>Plasma for ctDNA-MRD (PhasED-Seq)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Correlation of EOT MRD Status (+/-) with PFS & OS</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=150)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Successfully Identified PVs</td><td>150/156 (96%)</td></tr>
                                <tr><td>Diagnoses</td><td>DLBCL (90%), HGBL (9%), PBMCL (1%)</td></tr>
                                <tr><td>Median Age, years</td><td>67.5</td></tr>
                                <tr><td>IPI Distribution</td><td>Low: 22%, Low-Int: 29%, High-Int: 27%, High: 22%</td></tr>
                                <tr><td>Median Follow-up</td><td>31 months</td></tr>
                                <tr><td>24-month PFS (overall cohort)</td><td>74%</td></tr>
                                <tr><td>24-month OS (overall cohort)</td><td>86%</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Biomarker Insights</h2>
                    <p class="text-sm mb-2"><strong>Pretreatment ctDNA Levels:</strong></p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Higher levels associated with higher Ann Arbor Stage (I/II vs III/IV: 2.5% vs 5.7%, P=0.015).</li>
                        <li>Higher levels associated with higher IPI (0-2 vs 3-5: 2.2% vs 9.2%, P&lt;0.0001).</li>
                    </ul>
                    <p class="text-sm mb-2 mt-3"><strong>EOT ctDNA-MRD Status:</strong></p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>MRD-negative: 76% of patients.</li>
                        <li>MRD-positive: 24% of patients.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Prognostic Value of EOT ctDNA-MRD</h2>
                    <div class="table-container">
                        <h3 class="sub-section-title text-center">EOT MRD Status vs. Outcomes</h3>
                        <table>
                            <thead>
                                <tr><th>Outcome (2-year)</th><th>MRD+ (N=36)</th><th>MRD- (N=114)</th><th>HR (95% CI)</th><th>p-value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>PFS</td><td>28%</td><td>88%</td><td>9.7 (4.2-22.3)</td><td>&lt;0.0001</td></tr>
                                <tr><td>OS</td><td>50%</td><td>97%</td><td>10.6 (4.1-27.7)</td><td>&lt;0.0001</td></tr>
                            </tbody>
                        </table>
                    </div>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mt-3">
                        <li>In patients without complete response (CR) by imaging, MRD+ status was significantly prognostic for PFS (HR 7.6, 95% CI 3.6-16.3, p < 0.0001), suggesting ctDNA can adjudicate imaging results.</li>
                        <li>Among patients who were MRD- and achieved CMR at EOT, 2-year PFS and OS were 91% and 99%, respectively.</li>
                        <li>All patients who failed to achieve CMR and remained MRD+ experienced relapse.</li>
                        <li>ctDNA-MRD was prognostic for outcomes in all subgroups considered (e.g., source of baseline sample, best clinical response, IPI, sex, LDH, stage, extranodal disease).</li>
                        <li>In multivariate analysis (including ctDNA-MRD, IPI, best overall response), ctDNA-MRD was significantly and independently prognostic for PFS (HR 7.1, p&lt;0.0001) and OS (HR 5.1, p=0.00018).</li>
                    </ul>
                     <div class="km-plot-container text-center my-4">
                        <img src="Assets/KMCEHA (6).jpg" alt="Kaplan-Meier curves for PFS and OS by EOT MRD status" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/600x400/E0F2F7/0A2F5C?text=KM+Curves+Not+Available';">
                        <p class="text-xs meta-info mt-1">Figure: Kaplan-Meier curves for PFS and OS, stratified by EOT ctDNA-MRD status (Placeholder for actual image from abstract).</p>
                    </div>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>This study validated the prognostic value of PhasED-Seq-based ctDNA-MRD in a real-world multicenter 1L DLBCL cohort.</li>
                <li>ctDNA-MRD at EOT highlights the utility to confirm residual disease in patients without complete response by imaging.</li>
                <li>It also has the potential to identify patients who may benefit from consolidation therapy.</li>
                <li>These results support the integration of MRD as a standard component of response evaluation in 1L DLBCL treatment.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>1L, First-Line; CI, Confidence Interval; CMR, Complete Metabolic Response; ctDNA, Circulating Tumor DNA; DA-EPOCH-R, Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, Rituximab; DLBCL, Diffuse Large B-Cell Lymphoma; DNA, Deoxyribonucleic Acid; EOT, End of Treatment; HGBL, High-Grade B-Cell Lymphoma; HOVON, Stichting Hemato-Oncologie voor Volwassenen Nederland; HR, Hazard Ratio; IPI, International Prognostic Index; LBCL, Large B-Cell Lymphoma; LDH, Lactate Dehydrogenase; MRD, Measurable (Minimal) Residual Disease; OS, Overall Survival; PBMCL, Primary Mediastinal B-Cell Lymphoma; PFS, Progression-Free Survival; PhasED-Seq, Phased Variant Enrichment and Detection Sequencing; PV, Phased Variant; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Chamuleau M, Wang S, Nijland M, et al. Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national HOVON trial. Abstract #S240 presented at the European Hematology Association (EHA) Congress. June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA2025 Congress | Abstract #S240 | Abstract Release: 05/14/25 | Presentation: June 12-15, 2025</p>
            <p class="text-xs italic mt-1">This abstract is embargoed until Thursday, June 12, 2025, 08:00 CEST. For Research & Informational Purposes Only.</p>
        </div>
    </div>
    <script defer src="abstract_features.js"></script>
</body>
</html>